Portland General Electric (NYSE:POR) reported third-quarter adjusted earnings of $1.06 per diluted share and revised its 2026 adjusted earnings guidance to $3.18–$3.28 per share.
HUTCHMED (NASDAQ:HCM) received US Food and Drug Administration Orphan Drug Designation for sovleplenib to treat primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk.
California Water Service Group (NYSE:CWT) reported third-quarter 2026 revenue of $332.2 million, up 6.7% year over year, while net income increased to $65.4 million.
Fiverr (NYSE:FVRR) reported third-quarter 2026 revenue of $90.9 million, down 15.8% year over year, and raised its full-year financial guidance ranges.
ING (NYSE:ING) reported third-quarter 2026 net result of €1.850 billion, up 3.5% year over year, as profit before tax increased 5.7% to €2.705 billion.
Molecular Partners (NASDAQ:MOLN) plans to reduce its workforce by up to approximately 44%, affecting no more than 55 positions, as it increases its focus on targeted radiotherapy.
STMicroelectronics (NYSE:STM) reported third-quarter 2026 revenue of $3.76 billion, up 17.9% year over year, as operating income increased to $367 million.
Anheuser-Busch InBev (NYSE:BUD) reported third-quarter 2026 revenue of $16.51 billion, up 9.1% as reported, beating analysts' $16.24 billion estimate as underlying earnings per share increased 22.4% to $1.21.
Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 revenue growth of 8.4% at actual exchange rates and upgraded its full-year outlook to reflect foreign exchange benefits.
ASE Technology Holding (NYSE:ASX) reported unaudited third-quarter 2026 revenue of NT$244.161 billion, up 44.8% year over year and 27.8% from the previous quarter.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
